Literature DB >> 15095227

Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.

Christopher W Woods1, Allen C Cheng, Vance G Fowler, Mary Moorefield, Joyce Frederick, George Sakoulas, Venkata G Meka, Fred C Tenover, Peter Zwadyk, Kenneth H Wilson.   

Abstract

Clinical management of infective endocarditis (IE) is expected to become more difficult with the emergence of Staphylococcus aureus with reduced susceptibility to vancomycin (SARV) in the United States and worldwide. We report the strain characterization and treatment of a patient with SARV IE.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15095227     DOI： 10.1086/383027

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  11 in total

1.  Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mandy Wootton; T R Walsh; A P MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.

Authors:  Brian T Tsuji; Michael J Rybak; Kerry L Lau; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

4.  First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.

Authors:  S Al-Obeid; Q Haddad; A Cherkaoui; J Schrenzel; P François
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

5.  Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico.

Authors:  Alejandro Delgado; James T Riordan; Reena Lamichhane-Khadka; David C Winnett; Jennifer Jimenez; Kim Robinson; Frances G O'Brien; Stephanie A Cantore; John E Gustafson
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

Review 6.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

7.  Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Chia-Yu Chi; Tsai-Ling Lauderdale; Shih-Min Wang; Jing-Ming Wu; Yu-Jen Yang; Ching-Chuan Liu
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

Review 8.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

9.  Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus.

Authors:  Giuseppe Chesi; Andrea Colli; Carlos A Mestres; Gianpaolo Gambarati; Fabrizio Boni; Tiziano Gherli
Journal:  BMC Infect Dis       Date:  2006-07-26       Impact factor: 3.090

10.  Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers.

Authors:  Alexander Scherl; Patrice François; Yvan Charbonnier; Jacques M Deshusses; Thibaud Koessler; Antoine Huyghe; Manuela Bento; Jianru Stahl-Zeng; Adrien Fischer; Alexandre Masselot; Alireza Vaezzadeh; Francesca Gallé; Adriana Renzoni; Pierre Vaudaux; Daniel Lew; Catherine G Zimmermann-Ivol; Pierre-Alain Binz; Jean-Charles Sanchez; Denis F Hochstrasser; Jacques Schrenzel
Journal:  BMC Genomics       Date:  2006-11-22       Impact factor: 3.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.